0:000:00
<p>The Filtrate:</p><p><strong>Joel Topf</strong></p><p><strong>Swapnil Hiremath</strong></p><p><strong>Josh Waitzman</strong></p><p><strong>Nayan Arora</strong></p><p><strong>Sophia Ambruso</strong></p><p>With Special Guest:</p><p><strong>Brendon Neuen </strong>Super smart guy and clinical trialist</p><p><strong>Vlado Perkovic </strong>Lead author of FLOW and friend of NephJC</p><p>Editor </p><p><strong>Joel Topf</strong></p><p><strong>Show Notes</strong></p><p>The manuscript (<a target="_blank" href="https://www.nejm.org/doi/abs/10.1056/NEJMoa2403347">NEJM</a>): Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes</p><p>The acronym FLOW from the title: <em>evaluate renal </em><strong><em>F</em></strong><em>unction with semag</em><strong><em>L</em></strong><em>utide </em><strong><em>O</em></strong><em>nce </em><strong><em>W</em></strong><em>eekly</em> (<a href="https://x.com/kidney_boy/status/1793999889254519090">Twitter</a>)</p><p>Joel wrote a blog post p...